{
    "clinical_study": {
        "@rank": "161634", 
        "arm_group": [
            {
                "arm_group_label": "Panretinal photocoagulation", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Aflibercept intravitreal injections", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Proliferative diabetic retinopathy is a serious complication of diabetes mellitus, partly\n      consecutive to upregulation of vascular endothelial growth factor (VEGF) as a consequence of\n      retinal ischemia leads. Aflibercept has been approved by FDA and European medicine agency\n      for treatment of exudative age-related macular degeneration, another retinal disease\n      characterized by choroidal new vessels.\n\n      The aim of this pilot study is to evaluate the efficacy and the safety of Aflibercept\n      intravitreal injections compared to panretinal photocoagulation for proliferative diabetic\n      retinopathy."
        }, 
        "brief_title": "Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.", 
        "condition": "Naive Patients With Uncomplicated PDR.", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Retinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with diabetes mellitus type 1 or type 2 complicated by PDR\n\n          -  Male or female over 18 years\n\n          -  HbA1c <11% at study entry\n\n          -  Systolic blood pressure <160 mmHg and diastolic blood pressure <105 mmHg at study\n             entry\n\n          -  Backgrounds clear eye, pupil dilation and patient cooperation sufficient to allow\n             examination or fundus photographs of good quality\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to aflibercept or to any of the excipients\n\n          -  History of retinal laser (macular or panretinal photocoagulation), of intravitreal\n             injections, of vitrectomy in the eye studied\n\n          -  PDR associated with tractional retinal detachment in the eye studied\n\n          -  PDR associated with fibrovascular proliferation in the eye studied\n\n          -  Florid diabetic retinopathy\n\n          -  Eye infection or periocular active or suspected\n\n          -  Unbalanced glaucoma in the eye studied\n\n          -  Other eye disease in the eye studied\n\n          -  Patients with significant medical problems that may interfere with the evaluation of\n             the safety or efficacy of the treatment studied"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151695", 
            "org_study_id": "mEdICARE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Panretinal photocoagulation", 
                "intervention_name": "panretinal photocoagulation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Aflibercept intravitreal injections", 
                "intervention_name": "Aflibercept intravitreal injections", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Poitiers", 
                    "country": "France"
                }, 
                "name": "Chu de Poitiers"
            }, 
            "investigator": {
                "last_name": "Nicolas LEVEZIEL, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.", 
        "overall_contact": {
            "email": "nicolas.leveziel@chu-poitiers.fr", 
            "last_name": "Nicolas LEVEZIEL, MD, PhD", 
            "phone": "+33 (0)5.49.44.44.44"
        }, 
        "overall_official": {
            "affiliation": "Poitiers University Hospital", 
            "last_name": "Nicolas LEVEZIEL, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - French Health Products Safety Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with regression of retinal neovascularization between baseline and 12th month.", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Poitiers University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Poitiers University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}